Sunovion in Short
Sunovion Pharmaceuticals Inc. is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system (CNS) and respiratory disease areas and improve the lives of patients and their families. Sunovion's drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products including Latuda® (lurasidone HCl), LUNESTA® (eszopiclone), BROVANA® (aformoterol tartrate) Inhalation Solution, OMNARIS® (ciclesonide) Nasal Spray, ZETONNA® (ciclesonide) Nasal Aerosol, XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol and ALVESCO® (ciclesonide) Inhalation Aerosol.
Sunovion, an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at www.sunovion.com.
How we became Sunovion
In October 2009, Sepracor Inc., a U.S. pharmaceutical company with a focus in CNS and respiratory therapies, was acquired by Dainippon Sumitomo Pharma Co., Ltd. (DSP), a top ten Japanese pharmaceutical company based in Osaka, Japan. The move strengthened DSP's North American-based drug development pipeline and commercial capabilities, and brought together extensive expertise in two main therapeutic categories—disorders of the central nervous system (CNS) and respiratory diseases. In April 2010, DSP's original U.S. subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA) was merged into Sepracor. Sunovion is the new company born of this union.